Viridian TherapeuticsVRDN
VRDN
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
88% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 42
75% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 24
20% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 12 (+2) [Q4]
8% more funds holding
Funds holding: 165 [Q3] → 178 (+13) [Q4]
0.3% more ownership
Funds ownership: 114.63% [Q3] → 114.94% (+0.3%) [Q4]
12% less capital invested
Capital invested by funds: $1.99B [Q3] → $1.75B (-$246M) [Q4]
52% less call options, than puts
Call options by funds: $9.76M | Put options by funds: $20.4M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$38
203%
upside
Avg. target
$38
203%
upside
High target
$38
203%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Needham Serge Belanger 48% 1-year accuracy 58 / 122 met price target | 203%upside $38 | Buy Reiterated | 7 Jan 2025 |
Financial journalist opinion
Neutral
Business Wire
3 weeks ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 113,200 shares of the company's common stock to nine new emp.
Positive
Seeking Alpha
4 weeks ago
Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window
Viridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive and Thrive-2 trials bolster confidence, with VRDN-001 demonstrating rapid response and consistent efficacy in both active and chronic TED. Financially stable with a cash runway into 2027, Viridian is well-positioned for FDA approval, expected to be a significant catalyst for the stock.
Negative
Zacks Investment Research
1 month ago
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to loss of $1.35 per share a year ago.
Neutral
Business Wire
1 month ago
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. “We made tremendous progress in 2024 which was capped off by the positive and better-than-expected pivotal data for our lead TED program veligrotug in a.
Neutral
Business Wire
1 month ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 527,750 shares of the company's common stock to 15 new employees (the “Inducem.
Neutral
Business Wire
2 months ago
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company's key priorities and catalysts for 2025. “After a great year of execution across the portfolio, we enter 2025 poised to deliver on a number of important catalysts,” said Steve Mahoney, Viridian's President and CEO. “We believe that the positive and better-than-expect.
Positive
Seeking Alpha
3 months ago
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)
Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing VRDN-003, an improved subcutaneous version of veligrotug for TED patients, with phase 3 REVEAL-1 and REVEAL-2 topline data expected in early 2026. Promising pipeline candidates include FcRn inhibitors VRDN-006 and bispecific VRDN-008, targeting IgG-mediated autoimmune disorders with potentially superior efficacy.
Positive
Seeking Alpha
3 months ago
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation
Viridian's veligrotug delivered positive data from two phase 3 trials in active and chronic TED patients. The results from the THRIVE-2 trial in chronic TED patients show hints of differentiation to Tepezza with statistically significant effects on diplopia response and diplopia resolution. Veligrotug's results also provide clinical de-risking for next-generation, subcutaneously administered candidate VRDN-003, which I expect to be the key long-term growth driver for the TED franchise.
Positive
Seeking Alpha
3 months ago
Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)
Viridian Therapeutics, Inc.'s stock surged over 20% after key trial results came out before the bell on Monday. The study results triggered a rash of buy reissuances from analyst firms and improved the chances of FDA approval for the company's lead candidate in 2026. Even after the rally in VRDN stock on Monday, the stock remains undervalued given its potential market. The company also has a large cash balance.
Positive
Investors Business Daily
3 months ago
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell. The post Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease appeared first on Investor's Business Daily.
Charts implemented using Lightweight Charts™